Connection

Yuko Palesch to Stroke

Back to Details
This is a "connection" page, showing publications Yuko Palesch has written about Stroke.
Yuko Palesch
Connection Strength
3.904
Stroke
  1. Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. PLoS One. 2017; 12(10):e0187050.
    View in: PubMed
    Score: 0.250
  2. Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1321-7.
    View in: PubMed
    Score: 0.209
  3. A surrogate-primary replacement algorithm for response-adaptive randomization in stroke clinical trials. Stat Methods Med Res. 2017 Jun; 26(3):1078-1092.
    View in: PubMed
    Score: 0.206
  4. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013 Aug; 8(6):479-83.
    View in: PubMed
    Score: 0.186
  5. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013 06 20; 368(25):2432-3.
    View in: PubMed
    Score: 0.185
  6. Comments regarding the recent OAST article. Stroke. 2008 Jan; 39(1):e14; author reply e15.
    View in: PubMed
    Score: 0.126
  7. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis. Stroke. 2006 Aug; 37(8):2107-14.
    View in: PubMed
    Score: 0.114
  8. Applying a phase II futility study design to therapeutic stroke trials. Stroke. 2005 Nov; 36(11):2410-4.
    View in: PubMed
    Score: 0.108
  9. J-shape relation of blood pressure reduction and outcome in acute intracerebral hemorrhage: A pooled analysis of INTERACT2 and ATACH-II individual participant data. Int J Stroke. 2022 12; 17(10):1129-1136.
    View in: PubMed
    Score: 0.083
  10. Intensive blood pressure lowering with nicardipine and outcomes after intracerebral hemorrhage: An individual participant data systematic review. Int J Stroke. 2022 06; 17(5):494-505.
    View in: PubMed
    Score: 0.082
  11. National Institutes of Health Stroke Scale: An Alternative Primary Outcome Measure for Trials of Acute Treatment for Ischemic Stroke. Stroke. 2020 01; 51(1):282-290.
    View in: PubMed
    Score: 0.072
  12. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. JAMA Netw Open. 2019 09 04; 2(9):e1910769.
    View in: PubMed
    Score: 0.071
  13. Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. JAMA Neurol. 2019 07 01; 76(7):774-782.
    View in: PubMed
    Score: 0.070
  14. Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. Circulation. 2019 08 20; 140(8):658-664.
    View in: PubMed
    Score: 0.070
  15. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke. 2019 02; 14(2):207-214.
    View in: PubMed
    Score: 0.066
  16. Treatment effect on ordinal functional outcome using piecewise multistate Markov model with unobservable baseline: an application to the modified Rankin scale. J Biopharm Stat. 2019; 29(1):82-97.
    View in: PubMed
    Score: 0.065
  17. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19; 379(3):215-225.
    View in: PubMed
    Score: 0.065
  18. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018 02 22; 378(8):708-718.
    View in: PubMed
    Score: 0.063
  19. Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc. 2017 May 08; 6(5).
    View in: PubMed
    Score: 0.060
  20. A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3). Int J Stroke. 2017 10; 12(8):896-905.
    View in: PubMed
    Score: 0.060
  21. Power of an Adaptive Trial Design for Endovascular Stroke Studies: Simulations Using IMS (Interventional Management of Stroke) III Data. Stroke. 2016 12; 47(12):2931-2937.
    View in: PubMed
    Score: 0.058
  22. Endovascular Therapy of M2 Occlusion in IMS III: Role of M2 Segment Definition and Location on Clinical and Revascularization Outcomes. AJNR Am J Neuroradiol. 2017 Jan; 38(1):84-89.
    View in: PubMed
    Score: 0.058
  23. ALIAS (Albumin in Acute Ischemic Stroke) Trials: Analysis of the Combined Data From Parts 1 and 2. Stroke. 2016 09; 47(9):2355-9.
    View in: PubMed
    Score: 0.057
  24. The National Institutes of Health StrokeNet: A User's Guide. Stroke. 2016 Feb; 47(2):301-3.
    View in: PubMed
    Score: 0.055
  25. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016 Feb; 47(2):581-641.
    View in: PubMed
    Score: 0.055
  26. Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke: Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data. Stroke. 2015 Dec; 46(12):3416-22.
    View in: PubMed
    Score: 0.054
  27. Albumin Administration in Acute Ischemic Stroke: Safety Analysis of the ALIAS Part 2 Multicenter Trial. PLoS One. 2015; 10(9):e0131390.
    View in: PubMed
    Score: 0.054
  28. Outcome Differences between Intra-Arterial Iso- and Low-Osmolality Iodinated Radiographic Contrast Media in the Interventional Management of Stroke III Trial. AJNR Am J Neuroradiol. 2015 Nov; 36(11):2074-81.
    View in: PubMed
    Score: 0.053
  29. Imaging in StrokeNet: Realizing the Potential of Big Data. Stroke. 2015 Jul; 46(7):2000-6.
    View in: PubMed
    Score: 0.053
  30. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis. Stroke. 2015 Feb; 46(2):461-4.
    View in: PubMed
    Score: 0.051
  31. Evolution of practice during the Interventional Management of Stroke III Trial and implications for ongoing trials. Stroke. 2014 Dec; 45(12):3606-11.
    View in: PubMed
    Score: 0.051
  32. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. Radiology. 2014 Oct; 273(1):202-10.
    View in: PubMed
    Score: 0.049
  33. Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial. Stroke. 2014 Jun; 45(6):1791-8.
    View in: PubMed
    Score: 0.049
  34. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):567-74.
    View in: PubMed
    Score: 0.049
  35. Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke. 2014 May; 45(5):1408-14.
    View in: PubMed
    Score: 0.049
  36. Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial. Stroke. 2014 Mar; 45(3):759-64.
    View in: PubMed
    Score: 0.048
  37. Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial. Stroke. 2014 Feb; 45(2):444-9.
    View in: PubMed
    Score: 0.048
  38. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. 2013 Nov; 12(11):1049-58.
    View in: PubMed
    Score: 0.047
  39. Regression analysis of ordinal stroke clinical trial outcomes: an application to the NINDS t-PA trial. Int J Stroke. 2014 Feb; 9(2):226-31.
    View in: PubMed
    Score: 0.046
  40. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 07; 368(10):893-903.
    View in: PubMed
    Score: 0.045
  41. Covariate imbalance and adjustment for logistic regression analysis of clinical trial data. J Biopharm Stat. 2013; 23(6):1383-402.
    View in: PubMed
    Score: 0.045
  42. Measuring continuous baseline covariate imbalances in clinical trial data. Stat Methods Med Res. 2015 Apr; 24(2):255-72.
    View in: PubMed
    Score: 0.041
  43. The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis. Stroke. 2011 Jun; 42(6):1621-5.
    View in: PubMed
    Score: 0.040
  44. The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. Stroke. 2011 Jan; 42(1):119-27.
    View in: PubMed
    Score: 0.039
  45. Quantifying the cost in power of ignoring continuous covariate imbalances in clinical trial randomization. Contemp Clin Trials. 2011 Mar; 32(2):250-9.
    View in: PubMed
    Score: 0.039
  46. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2011 Jan; 42(1):227-76.
    View in: PubMed
    Score: 0.038
  47. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke. 2010 Nov; 41(11):2581-6.
    View in: PubMed
    Score: 0.038
  48. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke. 2010 Apr; 41(4):732-8.
    View in: PubMed
    Score: 0.037
  49. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke. 2009 Nov; 40(11):3541-6.
    View in: PubMed
    Score: 0.036
  50. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008 Oct; 7(10):875-84.
    View in: PubMed
    Score: 0.033
  51. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008 Sep 18; 359(12):1238-51.
    View in: PubMed
    Score: 0.033
  52. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008 Sep 18; 359(12):1225-37.
    View in: PubMed
    Score: 0.033
  53. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke. 2008 May; 3(2):130-7.
    View in: PubMed
    Score: 0.032
  54. Design of the economic evaluation for the Interventional Management of Stroke (III) trial. Int J Stroke. 2008 May; 3(2):138-44.
    View in: PubMed
    Score: 0.032
  55. Revascularization results in the Interventional Management of Stroke II trial. AJNR Am J Neuroradiol. 2008 Mar; 29(3):582-7.
    View in: PubMed
    Score: 0.032
  56. The albumin in acute stroke trial (ALIAS); design and methodology. Int J Stroke. 2007 Aug; 2(3):214-9.
    View in: PubMed
    Score: 0.031
  57. The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report. Biochem Soc Trans. 2006 Dec; 34(Pt 6):1323-6.
    View in: PubMed
    Score: 0.029
  58. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results. Stroke. 2006 Aug; 37(8):2100-6.
    View in: PubMed
    Score: 0.028
  59. Lessons from adult stroke trials. Pediatr Neurol. 2006 Jun; 34(6):446-9.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.